Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis

被引:176
作者
Yamamoto, N
Sakai, F
Kon, S
Morimoto, J
Kimura, C
Yamazaki, H
Okazaki, I
Seki, N
Fujii, T
Uede, T
机构
[1] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 3002698, Japan
[2] Hokkaido Univ, Inst Med Genet, Sapporo, Hokkaido 060, Japan
[3] Immunobiol Lab, Gunma, Japan
关键词
D O I
10.1172/JCI200317778
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
It has been shown that osteopontin (OPN) plays a pivotal role in the pathogenesis of rheumatoid arthritis (RA). However, the molecular mechanism of OPN action is yet to be elucidated. Splenic monocytes obtained from arthritic mice exhibited a significant capacity for cell migration toward thrombin-cleaved OPN but not toward full-length OPN. Migratory monocytes expressed alpha9 and alpha4 integrins. Since cleavage of OPN by thrombin exposes the cryptic epitope recognized by alpha9 and alpha4 integrins, we investigated the role of the cryptic epitope SLAYGLR in a murine RA model by using a specific antibody (MS) reacting to SLAYGLR sequence. The M5 antibody could abrogate monocyte migration toward the thrombin-cleaved form of OPN. Importantly, M5 antibody could inhibit the proliferation of synovium, bone erosion, and inflammatory cell infiltration in arthritic joints. Thus, we demonstrated that a cryptic epitope, the SLAYGLR sequence of murine OPN, is critically involved in the pathogenesis of a murine model of RA.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 49 条
[1]  
Badger AM, 2001, ARTHRITIS RHEUM-US, V44, P128, DOI 10.1002/1529-0131(200101)44:1<128::AID-ANR17>3.0.CO
[2]  
2-M
[3]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[4]   Identification of dual α4β1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin [J].
Bayless, KJ ;
Davis, GE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :13483-13489
[5]  
Bayless KJ, 1998, J CELL SCI, V111, P1165
[6]   Role of pro-inflammatory cytokines in rheumatoid arthritis [J].
Brennan, FM ;
Maini, RN ;
Feldmann, M .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (1-2) :133-147
[7]   Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis [J].
Campion, GV ;
Lebsack, ME ;
Lookabaugh, J ;
Gordon, G ;
Catalano, M ;
Borenstein, D ;
Caldwell, J ;
Cohen, SA ;
Cohen, SB ;
Fleischmann, R ;
Heller, MD ;
Howard, P ;
Jaffer, AM ;
Kaine, JL ;
Kitsis, E ;
Kopp, EJ ;
Moreland, LW ;
OHanlan, M ;
Prupas, M ;
Rosenberg, A ;
Rutstein, J ;
Sack, MR ;
Schiff, MH ;
Singleton, CM ;
Taborn, J ;
Tindall, E ;
Weaver, AL ;
Yocum, D .
ARTHRITIS AND RHEUMATISM, 1996, 39 (07) :1092-1101
[8]   Peptidomimetic antagonists of αvβ3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone [J].
Carron, CP ;
Meyer, DM ;
Engleman, VW ;
Rico, JG ;
Ruminski, PG ;
Ornberg, RL ;
Westlin, WF ;
Nickols, GA .
JOURNAL OF ENDOCRINOLOGY, 2000, 165 (03) :587-598
[9]   The role of osteopontin in the development of granulomatous lesions in lung [J].
Chiba, S ;
Rashid, MM ;
Okamoto, H ;
Shiraiwa, H ;
Kon, S ;
Maeda, M ;
Murakami, M ;
Inobe, M ;
Kitabatake, A ;
Chambers, AF ;
Uede, T .
MICROBIOLOGY AND IMMUNOLOGY, 2000, 44 (04) :319-332
[10]  
Conaway HH, 1996, J BONE MINER RES, V11, P1419